CD274 and lymphoma: PD1 and PD-L1 IgG2 AAbs had a sensitivity of 22% (8/36) and 19% (7/36), respectively, at a specificity of 100% (8/8) in lymphoma patients who responded to anti-PD1 therapy (Figure 6B).